MicroDose Technologies, Inc. (PRNewsFoto/MicroDose Technologies, Inc.)
MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ — MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose’s proprietary electronic inhaler technology and Vectura’s dry powder insulin formulation.
Posts from ‘August, 2008’
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ — MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose’s dry powder inhaler (DPI) technology announced in March 2008.